Loading...
•
Jun 30, 2022
89Bio Q2 2022 Earnings Report
Reported positive topline results from ENTRIGUE Phase 2 trial and strengthened financial resources.
Key Takeaways
89bio reported positive topline results from the ENTRIGUE Phase 2 trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) and strengthened financial resources, raising approximately $94.5 million in gross proceeds through an underwritten offering.
Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023.
ENTRIGUE data to be presented as a late-breaker at European Society of Cardiology Congress 2022.
ENLIVEN Phase 2b NASH trial enrollment completion expected in the third quarter of 2022 followed by topline data in the first quarter of 2023.
Completed underwritten offering, raising approximately $94.5 million in gross proceeds.
Forward Guidance
89bio expects to complete enrollment in the third quarter of 2022 with over 200 patients in the ENLIVEN Phase 2b trial and report topline data in the first quarter of 2023. The company also anticipates initiating a Phase 3 trial in SHTG in the first half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...